Nilotinib Stada

Nilotinib, the active ingredient in Nilotinib Stada, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of chronic myeloid leukemia in adult patients, particularly those who are resistant or intolerant to prior therapy.

GNH USA supplies Nilotinib Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers benefit from reliable logistics and responsive technical support.

Nilotinib is a targeted therapy that inhibits the BCR‑ABL tyrosine kinase pathway in chronic myeloid leukemia.

Chronic phase CML: reduces leukemic cell proliferation and achieves cytogenetic remission. Accelerated phase CML: provides disease control when prior TKIs fail. Blast phase CML: may induce hematologic response in combination with other agents. Philadelphia chromosome‑positive ALL: used under specialist supervision in selected patients.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: loose stools, often transient. - Rash: skin erythema or pruritus. - Fatigue: generalized tiredness. - Headache: mild cranial discomfort.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Pancreatitis: abdominal pain with elevated enzymes. - Hepatotoxicity: increased liver enzymes or jaundice. - Severe neutropenia: marked reduction in white blood cells increasing infection risk.

When prescribing Nilotinib, clinicians should observe several safety measures to minimize risk. - Cardiac monitoring: obtain baseline ECG and repeat periodically to detect QT prolongation. - Liver function: assess transaminases before treatment and monitor during therapy. - Blood counts: perform regular CBC to identify neutropenia or thrombocytopenia. - Drug interactions: avoid concomitant use of strong CYP3A4 inhibitors or QT‑prolonging agents. - Cardiovascular risk: evaluate history of ischemic heart disease before initiation. - Store at room temperature: keep in original container, protect from moisture and light.

Nilotinib interacts with several medicines, requiring careful management to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase Nilotinib plasma levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may substantially lower drug exposure. - QT‑prolonging drugs (e.g., amiodarone, sotalol): raise risk of serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may require dose adjustment. - Antacids or proton‑pump inhibitors: can affect absorption; separate dosing by at least 2 hours. - Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for muscle toxicity.